NSETrading Window29 Sept 2026 · 29 Sept 2026, 05:15 pm

Trading Window

Jubilant Pharmova Limited · JUBLPHARMA

✦ AI Summary

Jubilant Pharmova Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Analysis Scores

Earnings Impact5/10
Growth Catalyst5/10
Governance Concern5/10
Regulatory Risk5/10
Balance Sheet Risk5/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Jubilant Pharmova Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Attachments (1)

📄

JUBLPHARMA_29092026171506_ClosureofTradingWindowsigned.pdf

pdf

Download →
View document text
September 29, 2026 BSE Limited National Stock Exchange of India Limited Floor 25, P. J. Towers Exchange Plaza Dalal Street, Fort Bandra Kurla Complex Mumbai - 400 001 Bandra (E) Mumbai - 400 051 Scrip Code: 530019 Trading Symbol: JUBLPHARMA Sub: Intimation regarding closure of Trading Window Dear Sir/Madam, Pursuant to Regulation 9 read with Schedule B of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for Prevention of Insider Trading for regulating, monitoring and reporting of trading by insiders, the Trading Window for dealing in the securities of Jubilant Pharmova Limited ("Company") shall remain closed for all Designated Persons and their Immediate Relatives with effect from Thursday, October 1, 2026 and shall continue to remain closed till 48 hours after the declaration of the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended September 30, 2026 to the Stock Exchanges. Accordingly, the Designated Persons have been intimated not to trade in the securities of the Company during the aforesaid period of Trading Window closure. The date of the Board Meeting for consideration and approval of the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended September 30, 2026 shall be intimated to the Stock Exchanges in due course. The above information shall also be made available on the website of the Company at www.jubilantpharmova.com. This is for your information and records. Thanking you, Yours faithfully, For Jubilant Pharmova Limited Naresh Kapoor Company Secretary